Use the filters below to narrow your search.
Filter results
You can narrow down the results using the filters.
Topic
- (-) Legislation (93)
- Advertising (273)
- COVID-19 (163)
- Safety monitoring and information (97)
- Compliance and enforcement (66)
- Vaping hub (53)
- Manufacturing (52)
- Labelling and packaging (35)
- Scheduling (national classification system) (27)
- Import and export (26)
- Medicinal cannabis hub (25)
- Sunscreens (16)
- Shortages and supply disruptions (14)
- Weight loss products (14)
- Committees and advisory bodies (9)
- Cosmetics (5)
- Unique Device Identification (UDI) hub (4)
- Clinical trials (3)
- Fees and payments (2)
- Prescription opioids hub (2)
- Urogynaecological (transvaginal) surgical mesh hub (2)
- Breast implant hub (1)
Search
240 result(s) found, displaying 1 to 25
-
Regulatory decision noticesThis instrument is made under Schedule 5A to the Therapeutic Goods Regulations 1990 and Schedule 4 to the Therapeutic Goods (Medical Devices) Regulations 2002.
-
Media releasesThe TGA has updated its Advertising therapeutic goods on social media guidance to help advertisers to understand their responsibilities when promoting therapeutic goods via these platforms.
-
News articlesThis Legislation Amendment makes changes to the way testing of goods is conducted under the Therapeutic Goods Regulations 1990.
-
Regulatory decision noticesThe TGA has identified a discrepancy between the wording of the ‘POTAS1’ warning statement available in the Code Tables compared to the requirements for potassium chloride and glucosamine sulfate potassium chloride in the Therapeutic Goods (Permissible Ingredients) Determination (the Determination).
-
Media releasesWe have issued 10 infringement notices, totalling $198,000, to Midnight Health Pty Ltd (Midnight Health) for the alleged unlawful advertising of prescription-only weight-loss medicines.
-
Compliance undertakingsWe have accepted a court-enforceable undertaking from Midnight Health Pty Ltd in relation to the alleged unlawful advertising of prescription-only weight-loss medicines.
-
News articlesA review of the GMP Clearance backlog reduction strategies that have been implemented and ongoing monitoring and reporting communication.
-
Media releasesWe have issued 3 infringement notices totalling $59,400, to Victorian-based companies for the alleged unlawful advertising of therapeutic goods, in contravention of the Therapeutic Goods Act 1989.
-
News articlesThe GMP Clearance SID now contains additional data as well as progress information on the Compliance Verification (CV) backlog reduction strategy.
-
News articlesInformation on the completion of automatic extensions for Good Manufacturing Practice (GMP) clearances and next steps.
-
News articlesIn 2025, the Therapeutic Goods (Exempt Monographs) Amendment Determination was introduced under the Therapeutic Goods Act 1989. This amendment updates the 2021 determination to exempt specific labelling requirements in certain pharmacopoeial monographs.
-
News articlesTemporary risk-based strategies to expedite the reduction of the GMP Clearance Compliance Verification (CV) backlog commences today.
-
Media releasesThe TGA has accepted a court-enforceable undertaking from The Aussie Gelatin Company Pty Ltd (Aussie Gelatin) in relation to the alleged unlawful manufacture, supply and advertising of therapeutic goods.
-
Compliance undertakingsWe have accepted a court-enforceable undertaking from The Aussie Gelatin Company Pty Ltd (Aussie Gelatin) in relation to the alleged unlawful manufacture, supply and advertising of therapeutic goods.
-
News articlesTemporary risk-based strategies are being introduced to expedite the reduction of the Good Manufacturing Practice (GMP) Clearance Compliance Verification (CV) backlog.
-
News articlesFollowing a public consultation process , the TGA has adopted the following 19 international scientific guidelines.
-
BlogIn many cases, pharmacists and prescribers are able to provide or prescribe another approved medicine that is on the Australian Register of Therapeutic Goods (ARTG) or they can give a different strength or dosage of the same medicine.
-
BlogLike all goods available in Australia, therapeutic goods can sometimes experience problems. When this happens, we decide if a ‘market action’ is needed. A market action aims to correct the problem. There are four types of market actions you should be aware of.
-
BlogWhile we encourage health practitioners to prescribe approved therapeutic goods where possible, unapproved therapeutic goods can be accessed in limited circumstances.
In making these joint decisions to use an unapproved therapeutic good, your doctor is required to inform you of the potential benefits and risks. -
News articlesThe dual labelling period for some medicine ingredients is ending on 30 April 2025.
-
Regulatory decision noticesUpdate on the progress in reducing the backlog of GMP Clearance Compliance Verification (CV) applications.
-
Regulatory decision noticesThis instrument is made under subsection 7C(1) of the Therapeutic Goods Act 1989.
-
News articlesThe updated plan emphasises solidifying our collaborative processes, aligning expectations with industry, and improving our communication strategies.
-
Safety updatesInformation for health professionals about medicines with safety related updates to their Product Information.
-
Safety updatesInformation for health professionals about medicines with safety related updates to their Product Information.